Exchange: NASDAQ·Updated 08:57 AM EDT
HALO logo

HALO Halozyme Therapeutics Inc.

$110.10
$0.44
(0.40%)
Pre-Market
Prev Close $109.66
Reported EarningsAug 6
Mkt Cap$12.45B
Vol33,994.00

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
45

Neutral Sentiment

How do you feel about HALO?

Advertisement|Remove ads.